FDA approves first-of-its-kind blood cancer treatment 

It’s designed to help people who are running out of options.

The FDA has approved Johnson & Johnson’s Tecvayli, a new blood cancer treatment designed to help people with hard-to-treat multiple myeloma.

The challenge: Multiple myeloma is a deadly type of blood cancer that affects plasma cells in bone marrow. This can lead to problems fighting infections, weakened bones, kidney dysfunction, and other secondary complications.

Even if an initial treatment is effective, multiple myeloma usually comes back.

Every year in the US, about 34,500 people are diagnosed with multiple myeloma, and the standard treatment options are surgery, radiation therapy, and chemotherapy.

While these can send the cancer into remission, it usually comes back — at that point, a patient is said to have “relapsed multiple myeloma.” If a patient’s cancer doesn’t respond to treatment at all or stops responding to it, it becomes “refractory multiple myeloma.” 

Overall, the average five-year survival rate in the US has been about 55% in recent years.

What’s new? J&J’s blood cancer treatment is now approved to treat people with relapsed or refractory multiple myeloma who’ve already received at least four other lines of therapy.

These four lines must include three specific types of treatments: a ​​proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The J&J drug, Tecvayli, is a different kind of treatment, called a bispecific antibody.

J&J’s blood cancer treatment brings cancer cells and T cells together to help the immune system recognize and destroy tumors.

These antibodies can bind to two different targets at once — in the case of Tecvayli, those targets are BCMA (a protein found in high numbers on multiple myeloma cancer cells) and CD3 (a protein found on the immune system’s T cells).

By bringing cancer cells and T cells together, the blood cancer treatment helps the immune system recognize and destroy tumors, Saad Usmani, a senior investigator on an open-label, single-arm phase 2 trial, told the National Cancer Institute.

The trial involved 110 people  — all of whom had previously received at least three lines of treatment for their multiple myeloma — and 61.8% of them saw their tumors shrink in response to Tecvayli. 

Looking ahead: Now that the FDA has approved Tecvayli, J&J can begin making it available to people with hard-to-treat multiple myeloma — a company spokesperson told Reuters they expect the med to be ready for shipment around November 4.

The spokesperson also said the drug is expected to have a list price of $39,500 per month. Patients will need a 9- to 10-month course, which means the total cost will likely be between $355,500 and $395,000 (though insurance will likely cover most of the bill).

In addition to the high cost, the new blood cancer treatment also carries the risk of serious side effects, including cytokine release syndrome — that’s likely why it’s only approved for patients who have tried several other treatments first. 

The cost and risk may well be worth it to patients who’ve run out of effective treatment options, though.

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

Australia’s 30-year quest to unlock an ancient painkiller
A crocodile attack led to a 30-year partnership to develop a painkiller based on the Nyikina Mangala people’s traditional knowledge.
Experimental drug cuts heart disease risk factor by 96%
Eli Lilly’s experimental drug lepodisiran reduced blood levels of lipoprotein(a) by up to 96% in a small trial.
Human brains have a remarkable ability to rewire themselves following injury
Every brain injury is unique, as is every person’s path to recovery. A concussion specialist explains the science behind rehabilitation and recovery.
World’s first CRISPR therapy approved in UK
UK regulators have authorized CRISPR Therapeutics’ Casgevy, making it the world’s first approved CRISPR therapy.
Wegovy slashes heart attack risk by 28%
Novo Nordisk’s weight-loss drug Wegovy can reduce a person’s risk of a serious cardiovascular event by 20%.
Up Next
Subscribe to Freethink for more great stories